$18.08−0.66 (−3.52%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Denali Therapeutics (DNLI) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~160.6%/yr (FY21→FY23), net margin −43.9%. Worth your attention in FY25: Share count (+42.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼21.2%
−512.5
FY21→FY25CAGR —
Free cash flow ($M)▼16.1%
−422.1
FY21→FY25CAGR —
Diluted EPS▼15.6%
−2.97
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+42.1%
121.5mn → 172.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$9.5M
−40.3% YoY in FY25.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level Gross Operating Net
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 21,382.0 | 0.0 | 0.0 | 330,531.0 | 108,463.0 | 48,661.0 | — | — |
Cost of revenue | 285.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 21,097.0 | 0.0 | 0.0 | 330,531.0 | 108,463.0 | 48,661.0 | — | — |
Research & development | 404,872.0 | 418,778.0 | 396,440.0 | 423,876.0 | 358,732.0 | 265,353.0 | ▲5.6% | +12.1% |
Selling, general & admin | 146,739.0 | 136,564.0 | 105,438.0 | 103,354.0 | 90,475.0 | 79,059.0 | ▲29.5% | +14.6% |
Total operating expenses | 553,111.0 | 555,342.0 | 487,341.0 | 527,230.0 | 449,207.0 | 344,412.0 | ▲14.0% | +12.7% |
Operating incomefeeds ROC rank | −532,014.0 | −555,342.0 | −487,341.0 | −196,699.0 | −340,744.0 | −295,751.0 | ▼14.0% | — |
Other income, net | 217,693.0 | 42,904.0 | 64,636.0 | 51,505.0 | 14,774.0 | 0.0 | — | — |
Pretax income | −314,321.0 | −512,438.0 | −422,705.0 | −145,194.0 | −325,970.0 | −295,751.0 | ▼21.2% | — |
Income tax | — | 102.0 | 68.0 | 30.0 | 21.0 | −575.0 | ▲50.0% | +69.4% (22→25) |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −314,423.0 | −512,540.0 | −422,773.0 | −145,224.0 | −325,991.0 | −290,581.0 | ▼21.2% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.73 | −2.97 | −2.57 | −1.06 | −2.60 | −2.39 | ▼15.6% | — |
Diluted shares (mn) | 192.08 | 172.65 | 164.47 | 137.37 | 125.53 | 121.52 | ▲5.0% | +9.2% |
| Margins | ||||||||
Gross margin | 98.7% | — | — | 100.0% | 100.0% | 100.0% | — | — |
Operating margin | −2488.1% | — | — | −59.5% | −314.2% | −607.8% | — | — |
Net margin | −1470.5% | — | — | −43.9% | −300.6% | −597.2% | — | — |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

